Replies to post #748778 on NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

Mulholland has been pushing a different path. It aligns with that of the Australian MD with GBM. Existing agents including CIs combined with AI selected antigen based mRNA platforms (as best I can decode out of nebulous info). The tie in to melanoma is a clue.

Certainly a fair rebut, and what gives me pause in declaring this is definitely DCVax related.

The only thing is, those two items (the work you referenced and the Win-Glio program) seem like two separate initiatives. And the Win-Glio seems like what is more likely to be kicking off in May.

Nothing discernable, just an interesting development given the timing of all this information coming out.

[Lykiri]

Professor Paul Mulholland clinical studies in development:

July 18, 2024

1. Feasibility Phase II study of Standard of Electro-hyperthermia plus Standard of Care
2. Feasibility Phase II study Checkpoint inhibitor prior to Standard of Care in Glioblastoma
3. Following the feasibility studies: Phase II study of Checkpoint inhibitor plus Electro-hyperthermia
4. Citadel -123 Plus Electro-hyperthermia

Citadel- 123 = A Phase I clinical trial to assess the activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor (123I- ATT001) directly administered in subject with relapsed glioblastoma.

Launching Event of Oncothermia in the Philippines - Dr. Paul MULHOLLAND
min. 16.50

https://www.neurooncologycare.co.uk/?fbclid=PAZXh0bgNhZW0CMTEAAab8lJFAfGcGLOPBpKjo2ICb75PndBJBLJvlPudf51AVRlYHWyNviXzx5XU_aem_5x58Z1Dfd4x9nzPD1nTuYw

https://www.instagram.com/ldn_immunotherapy/